On 01 September 2011 the first patient with multiple sclerosis (MS) was dosed in a phase II clinical study that evaluates the efficacy of Namisol® on spasticity in MS patients. This study is conducted by the Centre for Human Drug Research in The Netherlands at, and in cooperation with, the VU University Medical Center, Amsterdam. The study is expected to be completed Q4 2012.